{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:07:35Z","timestamp":1698556055415},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":3676,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1999,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Owing to the lack of efficacious treatments for refractory anemia with an excess of blasts (RAEB), evaluation of other therapeutic strategies is necessary, especially in elderly patients. We report herein our experience with an oral triple drug regimen with cyclophosphamide 200 mg\/m<jats:sup>2<\/jats:sup> and methotrexate 20 mg\/m<jats:sup>2<\/jats:sup> once a week, and 6\u2010mercaptopurine 50 mg\/m<jats:sup>2<\/jats:sup> daily for the treatment of RAEB. Eighteen patients with a median age of 62 yr (range 17\u201380) received a triple drug regimen (TDR), and they were compared with 6 patients who received oxymetholone (2 mg\/m<jats:sup>2<\/jats:sup>\/d) and 9 who received supportive therapy only. Partial response was achieved in 45% of patients receiving TDR. In 77% of patients treated with TDR the number of bone marrow blasts decreased to &lt;5%; however, they persisted with trilineage dyspoietic morphologic changes. Median survival for TDR was 23 months (range 1\u201396), which was longer than that for the other groups. A slight rise in liver enzymes was the only side effect of TDR. TDR seems to be a useful alternative in patients with RAEB, a finding to be confirmed in further prospective studies.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1999.tb01749.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T10:14:28Z","timestamp":1279448068000},"page":"213-218","source":"Crossref","is-referenced-by-count":3,"title":["Refractory anemia with excess of blasts: increased survival when treated with cyclophosphamide, methotrexate and 6\u2010mercaptopurine"],"prefix":"10.1111","volume":"62","author":[{"given":"Abraham","family":"Majluf\u2010Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Vargas\u2010Vorackova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Labardini\u2010M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"The French\u2010American\u2010British (FAB) Cooperative Group: Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennet JM","year":"1982","journal-title":"Br J Haematol"},{"key":"e_1_2_1_3_2","first-page":"95","article-title":"Morphology and classification of the myelodysplastic syndromes and their pathologic variants","volume":"33","author":"Kouides PA","year":"1996","journal-title":"Semin Hematol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb06138.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07329.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis and prognostic factors in 370 patients","volume":"74","author":"Sanz GF","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050267"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830701)52:1<83::AID-CNCR2820520117>3.0.CO;2-9"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood.V82.10.2967.2967","article-title":"All\u2010trans retinoic acid in patients with myelodysplastic syndrome: Results of a pilot study","volume":"82","author":"Aul C","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02558.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320357"},{"key":"e_1_2_1_13_2","first-page":"196","article-title":"Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndrome","volume":"33","author":"Gassmann W","year":"1996","journal-title":"Semin Hematol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226672"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07524.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08254.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb04173.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900901)66:5<831::AID-CNCR2820660503>3.0.CO;2-E"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30332-0"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-5-689"},{"key":"e_1_2_1_22_2","first-page":"234","article-title":"Myelodysplastic syndromes. A prognostic factor analysis of 221 untreated patients","volume":"57","author":"Aul C","year":"1988","journal-title":"Blut"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-12-932"},{"key":"e_1_2_1_24_2","first-page":"85","article-title":"Chemotherapy and bone marrow transplantation for myelodysplastic syndromes","volume":"19","author":"Cheson BD","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08616.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07381.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30331-9"},{"key":"e_1_2_1_28_2","first-page":"601","article-title":"Effect of chemotherapy for the myelodysplastic syndrome","volume":"65","author":"Armitage O","year":"1981","journal-title":"Cancer Treatm Rep"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01007957"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(90)90133-T"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood.V71.3.703.703","article-title":"Randomized study of 13\u2010cis retinoic acid versus placebo in myelodysplastic disorders","volume":"71","author":"Koeffler HP","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_32_2","first-page":"186","article-title":"Clinical use of hematopoietic growth factors in the myelodysplastic syndromes","volume":"33","author":"Ganser A","year":"1996","journal-title":"Semin Hematol"},{"key":"e_1_2_1_33_2","first-page":"617","article-title":"Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580), administered at five\u2010day continuous infusion","volume":"47","author":"Egorin MJ","year":"1987","journal-title":"Cancer Res"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(91)90007-Y"},{"key":"e_1_2_1_35_2","first-page":"696","article-title":"Effect of long\u2010term treatment with recombinant human interleukin\u20103 in patients with myelodysplastic syndromes","volume":"7","author":"Ganser A","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309086999"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08909.x"},{"key":"e_1_2_1_38_2","first-page":"609","article-title":"Low\u2010dose melphalan for treatment of high risk myelodysplastic syndromes","volume":"10","author":"Omoto E","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_39_2","first-page":"11","article-title":"Oral induction and consolidation of acute myeloid leukemia with etoposide, 6\u2010thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5\u2010day TAD","volume":"8","author":"Ruutu T","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.7.982"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530040302"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197307122890205"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-58"},{"key":"e_1_2_1_44_2","first-page":"979","article-title":"Anabolic therapy in aplastic anemia","volume":"28","author":"Sanchez\u2010Medal L","year":"1966","journal-title":"Blood"},{"key":"e_1_2_1_45_2","first-page":"365","article-title":"Empleo de la oxymetolona a dosis bajas en el tratamiento de la anemia refractaria: Informe preliminar","volume":"10","author":"Romero\u2010Garc\u00eda F","year":"1965","journal-title":"Sangre"},{"key":"e_1_2_1_46_2","first-page":"775","article-title":"Further studies on the erythropoietic effect of androgens","volume":"65","author":"Gurney CW","year":"1965","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/206270a0"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<113::AID-AJH4>3.0.CO;2-Z"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(88)90303-2"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(90)90119-T"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1999.tb01749.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1999.tb01749.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:07:41Z","timestamp":1698502061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1999.tb01749.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["10.1111\/j.1600-0609.1999.tb01749.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01749.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}